Aptevo Therapeutics Inc (APVO) Stock Price, Quote & News

Company Profile

Aptevo Therapeutics Inc., a clinical-stage research and development biotechnology company, focuses on developing immunotherapeutic candidates for the treatment of various forms of cancer in the United States. The company develops its products using ADAPTIR and ADAPTIR-FLEX platforms to generate monospecific, bispecific, and multi-specific antibody candidates capable of enhancing the human immune system against cancer cells. Its lead clinical blood cancer candidate is mipletamig that is in Phase...

Industry: Biotechnology

Sector: Healthcare

Phone: 206 838 0500

Fax: 206 838 0503

Website: aptevotherapeutics.com

Address:

2401 4th Avenue, Suite 1050, Seattle, United States

Gest1010 Apr. 24 at 11:15 PM

$ELAB I am scary Bio stocks, $APVO $IXHL $IOBT all lost money

0 · Reply

Mind129 Apr. 19 at 6:18 AM

$APVO when next RS is coming of this SHIT

0 · Reply

LagerHound Apr. 17 at 5:08 PM

$APVO

0 · Reply

ProfessorDman1 Apr. 17 at 12:43 AM

$APVO nobody wanted this with me sub $4 earlier this month … I even posted many times about it with DD analysis.. they will talk about it once it’s into double digits lol 😂 .. gave The idea at bottomed when I buy I post and not already up 50% for the day or weekly .. sub $4 same $MNTS 130%+ .50-.56 $CMCT 110% runner List goes on Have a great night

1 · Reply

BLOCKS77 Apr. 17 at 12:05 AM

$APVO nice close 👏

0 · Reply

BLOCKS77 Apr. 16 at 11:51 PM

$APVO

0 · Reply

ProfessorDman1 Apr. 16 at 10:22 PM

$APVO $BIRD $CMCT $MNTS $ONFO ( OBAI gonna get that squeeze play and news 🗞️ could drop at any moment: )

0 · Reply

ProfessorDman1 Apr. 16 at 8:12 PM

$APVO 3.85-4 swing idea at bottomed buy entrance : we are near $6 now ..

1 · Reply

ProfessorDman1 Apr. 16 at 7:39 PM

$MNTS swing idea gained 130% so far $CMCT earlier gave that 110% $APVO swing up 50%+ now $ONFO missed it ran 300% $BIRD yesterday went 1000% single runner OBAI could run 5x-10x from here .70 cents IMO

0 · Reply

Smug_Vortex Apr. 16 at 6:39 PM

$APVO

0 · Reply

Aptevo Provides State of the Business Report and 2025 Financial Results

Mar 19, 2026, 8:05 AM EDT - 5 weeks ago

Aptevo to Participate in March 2026 Conferences

Mar 10, 2026, 8:05 AM EDT - 6 weeks ago

Mipletamig Delivers Compelling 86% Clinical Benefit Rate and No CRS as Evaluable AML Patient Data increases by Nearly 50%

Feb 3, 2026, 8:05 AM EST - 2 months ago

Aptevo Announces Executive Leadership Transitions to Support Next Phase of Growth

Jan 9, 2026, 8:05 AM EST - 3 months ago

Aptevo Therapeutics Secures $60 Million Equity Line of Credit to Support Multispecific Portfolio Advancement, Increase Strategic Optionality

Dec 26, 2025, 8:05 AM EST - 4 months ago

Aptevo Therapeutics Announces 1-for-18 Reverse Stock Split

Dec 9, 2025, 8:05 AM EST - 4 months ago

Aptevo Therapeutics Highlights Compelling Safety and Strong Remission Rates for Mipletamig in Frontline AML at ASH 2025

Nov 10, 2025, 8:05 AM EST - 5 months ago

Aptevo Debuts First Trispecific Antibody Candidate, APVO451, with Preclinical Data Demonstrating Immune Activation in Hard-to-Treat Solid Tumors

Nov 6, 2025, 8:05 AM EST - 6 months ago

Aptevo Therapeutics Reports 3Q25 Financial Results And Provides A Business Update

Oct 8, 2025, 8:20 AM EDT - 7 months ago

Aptevo Presenting Scientific and Clinical Updates at SITC and ASH, also Participating in Leading Financial and Industry Conferences in the Fourth Quarter

Sep 16, 2025, 8:30 AM EDT - 7 months ago

Mipletamig Delivers 100% Remission Rate in Cohort 3 of RAINIER Trial for AML

Sep 4, 2025, 8:45 AM EDT - 8 months ago

Aptevo Unveils Two Next-Generation, Industry Leading Trispecifics, Expanding CD3 Oncology Pipeline to Five Molecules

Aug 13, 2025, 8:05 AM EDT - 9 months ago

Aptevo Highlights APVO442, a CD3-Directed Preclinical Candidate for Prostate Cancer

Aug 11, 2025, 8:05 AM EDT - 9 months ago

Aptevo Therapeutics Reports 2Q25 Financial Results And Provides A Business Update

Jun 20, 2025, 11:30 AM EDT - 11 months ago

Aptevo Therapeutics Announces Closing of $8 Million Offering Priced At-the-Market Under Nasdaq Rules

Jun 20, 2025, 8:55 AM EDT - 11 months ago

Aptevo Expands Differentiated CD3 Portfolio with APVO455, Advancing a Suite of Targeted T-cell Engagers

Jun 20, 2025, 8:01 AM EDT - 11 months ago

Smith & Wesson Brands Posts Weak Q4 Results, Joins Aptevo Therapeutics And Other Big Stocks Moving Lower In Friday's Pre-Market Session

SWBI

Jun 18, 2025, 1:34 PM EDT - 11 months ago

Aptevo More Than Doubles After Favorable Results in Leukemia Study

Jun 18, 2025, 11:37 AM EDT - 11 months ago

Aptevo Therapeutics Touts Data From Investigational Drug Trial For Aggressive Blood Cancer

Jun 18, 2025, 10:52 AM EDT - 11 months ago

Aptevo Therapeutics Announces $8 Million Offering Priced At-the-Market Under Nasdaq Rules

Jun 18, 2025, 8:01 AM EDT - 11 months ago

Mipletamig Demonstrates Compelling Clinical Activity in Frontline AML

Jun 13, 2025, 8:05 AM EDT - 11 months ago

Aptevo Participating in the BIO International Convention

May 22, 2025, 8:05 AM EDT - 1 year ago

Aptevo Therapeutics Announces 1-for-20 Reverse Stock Split as part of Nasdaq Compliance Plan

May 15, 2025, 8:05 AM EDT - 1 year ago

Aptevo Therapeutics Reports 1Q25 Financial Results And Provides an Update on Mipletamig

May 8, 2025, 8:45 AM EDT - 1 year ago

Aptevo Therapeutics Provides Program Update for Bispecific APVO711, a PD-L1 X CD40 that Combines a Checkpoint Inhibitor and Immune Activation

Apr 22, 2025, 4:05 PM EDT - 1 year ago

Aptevo Therapeutics Announces the Closing of $2.0 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules

Apr 21, 2025, 2:40 PM EDT - 1 year ago

Aptevo Therapeutics $2.0 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules

Apr 4, 2025, 4:05 PM EDT - 1 year ago

Aptevo Therapeutics Announces the Closing of $2.1 Million Registered Direct Offering and Concurrent Private Placement Priced At-The-Market Under Nasdaq Rules

Apr 3, 2025, 8:50 AM EDT - 1 year ago

Aptevo Therapeutics $2.1 Million Registered Direct Offering and Concurrent Private Placement Priced At-The-Market Under Nasdaq Rules

Mar 20, 2025, 8:35 AM EDT - 1 year ago

RAINIER Trial Data Update: Two Additional AML Patients Achieve Remission Within 30 Days of Treatment

Mar 18, 2025, 8:05 AM EDT - 1 year ago

Aptevo Highlights APVO603: A Novel Bispecific Antibody Targeting 4-1BB and OX40 for Enhanced Solid Tumor Immunotherapy

Mar 6, 2025, 8:00 AM EST - 1 year ago

Aptevo to Participate in March Conferences

Feb 15, 2025, 6:59 PM EST - 1 year ago

Aptevo Therapeutics Interview to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV

Feb 14, 2025, 8:05 AM EST - 1 year ago

Aptevo Therapeutics Reports 2024 Financial Results And Provides A Business Update

Jan 15, 2025, 8:00 AM EST - 1 year ago

Aptevo's Peter Pavlik, PhD, Chairing Session on "Bi and Multispecific Biologics" at Cambridge Healthcare Institute's Pep Talk 2025

Dec 12, 2024, 12:50 PM EST - 1 year ago

Aptevo Therapeutics Announces Exercise of Warrants for $6.2 Million Gross Proceeds

Dec 12, 2024, 9:00 AM EST - 1 year ago

100% of Patients Achieve Remission Within 30 Days in Cohort 1 of Bispecific Mipletamig Frontline AML Trial

Dec 4, 2024, 8:35 AM EST - 1 year ago

Bispecific Antibody, APVO442, Differentiated to Treat Prostate Cancer with Precision Tumor Targeting and Reduced Risk of Side Effects

Nov 29, 2024, 9:55 AM EST - 1 year ago

Aptevo Therapeutics Announces 1-for 37 Reverse Stock Split As Part of Nasdaq Compliance Plan

Nov 26, 2024, 8:35 AM EST - 1 year ago

Proving the Concept: Aptevo Technology, Pipeline, to Exemplify the Speed and Power of Modular Biotherapeutics at Presentation

Nov 22, 2024, 8:35 AM EST - 1 year ago

Aptevo Highlights the Potential of the Company's Robust Portfolio in Cancer Immunotherapy, the Success of Bispecifics as a Category, and Their Growing Importance in the Oncology Treatment Paradigm

Nov 20, 2024, 8:35 AM EST - 1 year ago

First Patient Dosed in Aptevo's Ongoing RAINIER Trial Achieves 90% Reduction in Leukemic Blasts Within the First 30 Days of Treatment, Continues Overall Efficacy Trend Seen in Prior Mipletamig AML Studies

Nov 11, 2024, 8:15 AM EST - 1 year ago

First-in-Class Bispecific Antibody, ALG.APV-527, Meets Important Trial Endpoints in Phase 1 Solid Tumor Trial

Nov 7, 2024, 8:05 AM EST - 1 year ago

Aptevo Therapeutics Reports 3Q 2024 Financial Results and Provides a Business Update

Sep 18, 2024, 4:05 PM EDT - 1 year ago

Aptevo Therapeutics Announces Closing of $3.0 Million Offering Priced At-the-Market Under Nasdaq Rules

Sep 16, 2024, 8:05 PM EDT - 1 year ago

Aptevo Therapeutics Announces $3.0 Million Offering Priced At-the-Market Under Nasdaq Rules

Aug 13, 2024, 8:05 AM EDT - 1 year ago

Phase 1b/2 "RAINIER" Frontline Acute Myeloid Leukemia (AML) Trial Initiated

Aug 8, 2024, 8:05 AM EDT - 1 year ago

Aptevo Therapeutics Reports 2Q 2024 Financial Results and Provides a Business Update

Jul 1, 2024, 4:20 PM EDT - 1 year ago

Aptevo Therapeutics Announces Closing of $2.75 Million Offering

Jun 28, 2024, 9:20 AM EDT - 1 year ago

Aptevo Therapeutics Announces $2.75 Million Offering Priced At-the-Market Under Nasdaq Rules

Gest1010 Apr. 24 at 11:15 PM

$ELAB I am scary Bio stocks, $APVO $IXHL $IOBT all lost money

0 · Reply

Mind129 Apr. 19 at 6:18 AM

$APVO when next RS is coming of this SHIT

0 · Reply

LagerHound Apr. 17 at 5:08 PM

$APVO

0 · Reply

ProfessorDman1 Apr. 17 at 12:43 AM

1 · Reply

BLOCKS77 Apr. 17 at 12:05 AM

$APVO nice close 👏

0 · Reply

BLOCKS77 Apr. 16 at 11:51 PM

$APVO

0 · Reply

ProfessorDman1 Apr. 16 at 10:22 PM

$APVO $BIRD $CMCT $MNTS $ONFO ( OBAI gonna get that squeeze play and news 🗞️ could drop at any moment: )

0 · Reply

ProfessorDman1 Apr. 16 at 8:12 PM

$APVO 3.85-4 swing idea at bottomed buy entrance : we are near $6 now ..

1 · Reply

ProfessorDman1 Apr. 16 at 7:39 PM

0 · Reply

Smug_Vortex Apr. 16 at 6:39 PM

$APVO

0 · Reply

johnny6nine Apr. 16 at 3:36 PM

$APVO gonna need a real big PUMP to get out of this pig!🐖

0 · Reply

Yth4389 Apr. 15 at 7:49 PM

$APVO Uppity!

0 · Reply

BLOCKS77 Apr. 15 at 7:42 PM

$APVO 👀

0 · Reply

ProfessorDman1 Apr. 15 at 6:35 PM

$APVO 3.85-4 swing idea from earlier this month with DD and analysis at bottomed BUY entrance = it’s just keep going up now 5.40 HOD ✅

0 · Reply

ProfessorDman1 Apr. 15 at 11:52 AM

$APVO gave this DD analysis 3.85-4.20 range earlier this month: it was weekly up and down that range and you had opportunities to buy in 3.85-4.20 which I called the bottom BUY ins now 5.20 📖☝️ $LNKS next thing you will see it will be in the $3-5 range ✅

0 · Reply

ProfessorDman1 Apr. 14 at 11:14 PM

$APVO finally my swing idea from earlier this month is going : 3.85-4.20 buy analysis > $5+ as my 1st target it’s here now

0 · Reply